Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announced

Divi's Laboratories reported a consolidated net profit at Rs 751 crore in the March-ended quarter, a 13% YoY growth from Rs 662 crore reported in the year ago period. The profit after tax (PAT) is attributable to shareholders of the company.

The company's revenue from operations in Q4FY26 was up 10% to Rs 2,831 crore, compared to Rs 2,585 crore posted in the corresponding quarter of the previous financial year.

The drug maker recommended a final dividend of Rs 30 per equity share for the financial year 2025-26, subject to approval of the members at the 36th Annual General Meeting (AGM). The record date for the purpose of the payment of dividend is July 24, 2026.

The PAT surged 29% on a sequential basis in the quarter under review compared to Rs 583 crore in Q3FY26 while the topline increased 8% quarter-on-quarter versus Rs 2,585 crore in the October-December quarter of FY26.

The company incurred expenses of Rs 2,023 crore in the quarter under review versus Rs 1,838 crore in Q3FY26 and Rs 1,807 crore in Q4FY25. The expenses were made on items like materials consumed, purchases of stock-in-trade, employee benefits and finance costs.

For the current quarter, Divi's forex gain stood at Rs 90 crores as against a forex gain of Rs 10 crores for the corresponding quarter of the previous year.

For the financial year 2025-26, the company earned a consolidated total income of Rs 11,067 crore as against a consolidated total income of Rs 9,712 crore for the previous financial year. Profit before tax (PBT) for the current financial year amounted to t 3388 crores (after the impact of labour codes oft 74 Crores) as against Rs 2,916 crores for the previous financial year.

Profit After Tax (PAT) for the current financial year is Rs 2,568 crores as against Rs 2,191 crores for previous financial year. For the current financial year, the forex gain of Rs 211 crore against a gain of Rs 48 crore for the previous financial year.

(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)